Salbutamol dry-powder inhalation - Dura/Spiros

Drug Profile

Salbutamol dry-powder inhalation - Dura/Spiros

Alternative Names: Albuterol dry-powder inhalation - Dura/Spiros; Albuterol Spiros

Latest Information Update: 02 Oct 2000

Price : $50

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Dura Pharmaceuticals; Spiros Development Corporation II
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 02 Oct 2000 Discontinued-preregistration for Asthma in USA (Inhalation)
  • 07 Mar 2000 Dura announces intention to acquire Spiros Development Corporation II and discontinue development of Albuterol SpirosTM
  • 09 Dec 1999 A study in asthmatic patients has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top